Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Botensilimab, Balstilimab and Regorafenib (BBR) in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Who Progressed on Prior Chemotherapy

NCT05672316 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05672316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05672316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Botensilimab, Balstilimab and Regorafenib (BBR) in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Who Progressed on Prior Chemotherapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 11, 2023
Completion date
December 1, 2026
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal adenocarcinoma, advanced microsatellite stable colorectal carcinoma, metastatic colorectal adenocarcinoma, metastatic microsatellite stable colorectal carcinoma, stage iii colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8